


Appendix Figures to the Tufts-CEVR HEOR Leaders Survey


January 21, 2026

By company size


Appendix Figure 1.




Appendix Figure 2




Appendix Figure 3




Appendix Figure 4




Appendix Figure 5




Appendix Figure 6




Appendix Figure 7




Appendix Figure 8




Appendix Figure 9



Appendix Figure 10




Appendix Figure 11




By Market access & marketing vs. Medical Affairs & R&D


Appendix Figure 12




Appendix Figure 13



Appendix Figure 14




Appendix Figure 15




Appendix Figure 15

Have you or your team shared health care economic information (HCEI) about prescription drugs to payers or formulary decision-makers under the provisions of Section 3037 of the 21st Century Cures Act (Cures 3037, formerly FDAMA 114)?




Appendix Figure 16


In your opinion, how clearly does the Cures 3037 legislation explain which promotions can be submitted?




Appendix Figure 17




Appendix Figure 18



Appendix Figure 19



Appendix Figure 20



Appendix Figure 21

